Jacques Sivignon
Partner | Paris
Jacques Sivignon

Mr. Sivignon's principal activity is acting for multinational clients in complex commercial litigation, product liability, industrial risk and post-acquisition matters with a particular focus on pharmaceutical and healthcare industries. Mr. Sivignon also represents funds, investment advisers and related entities in investors’ litigation, securities and other financial disputes. His practice includes advising clients on compliance issues and working on a number of investigations dealing with corruption, fraud and violations of securities regulation.

Mr. Sivignon also acts as counsel for various state entities and multinational clients in ICC arbitrations concerning general corporate, license, construction and energy-related disputes. His practice includes the setting aside or enforcement of international arbitration awards, including attachment and tracing of assets.

Mr. Sivignon is recognized among the leading litigation lawyers in France by Best Lawyers 2025. He is recommended in Chambers Europe 2024 for his work in dispute resolution in France as well as in The Legal 500 EMEA 2024.

Prior to joining Dechert, Mr. Sivignon was a member of the International Litigation/Arbitration Department in the Paris office of another international law firm. He has also worked in the firm's Brussels and Sydney offices.

  • A global leader in patient-focused medical innovations for structural heart disease and artificial heart valves in product liability litigation.
  • A medical device producer in product liability actions and in a subsequent inquiry conducted by the national health agency (ANSM) regarding the safety of certain machines.
  • A global dermatological company in a post-acquisition dispute related to milestone payments linked with the development of a pharmaceutical product.
  • A pharmaceutical group in a dispute related to the supply of active substances.
  • The subsidiary of a Fortune 500 pharmaceutical company with an internal investigation examining the relationship of its French subsidiary with health care professionals and compliance with French regulations on corporate hospitality and gifts.
  • A Fortune 500 medical device manufacturer in a large anti-corruption internal investigation into the company’s discount and sales practices which the French anti-fraud authority considered breached French law. Potential FCPA violations were also investigated.
  • A leading pharmaceutical company in a US$500 million dispute arising out of the termination of a co-development agreement for a new product. 
  • An Asian manufacturer of electric components in a product liability dispute and worldwide product recall case. 
  • A US fund seeking to enforce an English decision against foreign governments’ instrumentalities in France.
  • A French engineering group in an ICC arbitration relating to claims for commissions by a purported agent in the procurent of large infrastructor project in the EUA.
  • A European construction group in an ad hoc arbitration and in proceedings to set aside the favorable award obtained before French Courts.
  • A French multinational retail group in a strategic corporate litigation with partners in the Middle East.

Includes matters handled at Dechert or prior to joining the firm.

  • M&A and Compliance, Institut du Risk & Compliance conference – Paris (June 10, 2021)
  • WebTV Forbes Interview "M&A : Etre Attentif Aux Enjeux De Compliance" — Paris, France (October 5, 2020) 
  • Life Sciences Academy — Paris, France (December 3, 2019)
  • Life Sciences Academy — Paris, France (October 2, 2018) 
  • Transparence et confidentialité : les défis de l'arbitrage  — Les rencontres de l'Arbitrage et du Contentieux, Paris (February 4, 2016)
  • Le contentieux au coeur de la stratégie de l'entreprise — Les rencontres de l'Arbitrage et du Contentieux, Paris (February 4, 2016)
  • Entreprises européennes: le défi américain de la Compliance — Organised by Université Panthéon-Assas and l'Ecole de Droit et de Management de Paris, Université Panthéon-Assas, Paris (June 5, 2015)
  • Les Rencontres de l'Arbitrage et du Contentieux -Contentieux multijuridictionnels — Organised by Option Finance, Paris (January 29, 2015)
  • The Paris Civil Court of Justice holds Sanofi liable in the first French-style class action case in the health care sector – L’Usine Nouvelle (February 11, 2022)
  • Reforming France’s Anti-Corruption Laws: Times are Changing (Again!) – Dechert OnPoint (January 5, 2022)
  • Force majeure in contractual matters in the context of the Covid-19 epidemic –  L’Usine Nouvelle (December 9, 2020)
  • France's CJIP guidelines leave little doubt that France will be an active player in global anti-corruption enforcement – ICLG (January 7, 2020)
  • Reform of the regime of the brutal rupture of established commercial relations –  L’Usine Nouvelle (September 25, 2019)
  • Navigating French Internal Investigations and Self-Reporting - French Authorities Issue New Guidance – Dechert OnPoint (August 7, 2019)


Services Industries
    • New York University School of Law, LL.M., 1996
    • University of Paris Nanterre - Paris X, Maîtrise de Droit des Affaires, 1995, with Honors
    • Paris
    • New York
    • French
    • English
    • Greek